<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818686</url>
  </required_header>
  <id_info>
    <org_study_id>0144</org_study_id>
    <secondary_id>2016-001633-27</secondary_id>
    <nct_id>NCT02818686</nct_id>
  </id_info>
  <brief_title>TD-1473 for Active Ulcerative Colitis (UC)</brief_title>
  <official_title>A Phase 1b Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Plasma Exposure of TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and&#xD;
      pharmacodynamics (PD) of TD-1473 in subjects with moderately-to-severely active UC over 28&#xD;
      days. This exploratory study will also serve as a signal seeking endeavor to demonstrate&#xD;
      biologic effect associated with TD-1473 through biomarker analysis and clinical, endoscopic,&#xD;
      and histologic assessments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 3, 2016</start_date>
  <completion_date type="Actual">March 29, 2018</completion_date>
  <primary_completion_date type="Actual">March 29, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-emergent Adverse Events (TEAE)</measure>
    <time_frame>Baseline to end of follow-up (a maximum of 42 days)</time_frame>
    <description>Number of participants who experience one or more treatment-emergent Adverse Events (TEAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Moderate or Severe Treatment-emergent Adverse Events (TEAE)</measure>
    <time_frame>Baseline to end of follow-up (a maximum of 42 days)</time_frame>
    <description>Number of participants who experience one or more moderate or severe treatment-emergent Adverse Events (TEAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Treatment-emergent Adverse Events (TEAE)</measure>
    <time_frame>Baseline to end of follow-up (a maximum of 42 days)</time_frame>
    <description>Number of participants who experience one or more serious treatment-emergent Adverse Events (TEAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Measurements</measure>
    <time_frame>Baseline to end of follow-up (a maximum of 42 days)</time_frame>
    <description>Number of participants who experienced a Clinically Significant Clinical Laboratory Measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Baseline to Day 14</time_frame>
    <description>Number of participants who experienced a Clinically Significant Electrocardiogram (ECG) Result</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Baseline to end of follow-up (a maximum of 42 days)</time_frame>
    <description>Number of participants who experienced a Clinically Significant Vital Sign Measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax in plasma</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Maximum Observed Plasma Concentration of TD-1473</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax in plasma</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Time to Reach Maximum Observed Plasma Concentration (Cmax) of TD-1473</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tlast in plasma</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Time to Last Quantifiable Concentration of TD-1473</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctrough in plasma</measure>
    <time_frame>Day 14 (Pre-dose)</time_frame>
    <description>Trough Concentration of TD-1473</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-4 in plasma</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Area Under the Concentration-time Curve from Time Zero to 4 hours Post-Dose of TD-1473</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctissue in plasma</measure>
    <time_frame>Day 28</time_frame>
    <description>Tissue Concentration of TD-1473</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>Baseline, Day 14 and Day 28</time_frame>
    <description>Mean Change in Serum C-reactive Protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Calprotectin</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Mean Change in Fecal Calprotectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Mayo score</measure>
    <time_frame>Baseline, Day 14 and Day 28</time_frame>
    <description>Mean Change in Partial Mayo Score</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Ulcerative Colitis, Active Moderate</condition>
  <condition>Ulcerative Colitis, Active Severe</condition>
  <arm_group>
    <arm_group_label>TD-1473 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects will be randomized to receive low-dose TD-1473 orally daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1473 mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects will be randomized to receive mid-dose TD-1473 orally daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1473 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects will be randomized to receive high-dose TD-1473 orally daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 subjects will be randomized to receive placebo orally daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1473</intervention_name>
    <arm_group_label>TD-1473 high dose</arm_group_label>
    <arm_group_label>TD-1473 low dose</arm_group_label>
    <arm_group_label>TD-1473 mid dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a history of ulcerative colitis diagnosis at least 3 months prior to screening&#xD;
&#xD;
          -  Is intolerant, refractory, or only partially responsive to aminosalicylates,&#xD;
             corticosteroids, immunomodulators, or biologics. If subject is currently receiving an&#xD;
             oral aminosalicylate, he or she is eligible and can stay on that dose of&#xD;
             aminosalicylate provided the dose has been stable for at least 2 weeks prior to&#xD;
             screening. If the subject is currently receiving an oral corticosteroid, he or she is&#xD;
             eligible if the dose is equivalent to or less than prednisone 20 mg/day or budesonide&#xD;
             9 mg/day and stable for at least 2 weeks prior to screening sigmoidoscopy if the&#xD;
             subject has been on corticosteroids for more than 2 weeks.&#xD;
&#xD;
          -  Has a rectal bleeding score ≥ 1 and a bowel frequency score ≥ 1 on the&#xD;
             patient-reported outcome 2 (PRO2) on screening sigmoidoscopy day and on Day 1 in&#xD;
             addition to a modified Mayo endoscopic subscore of ≥ 2 during screening&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test and either abstain&#xD;
             from sexual intercourse or use a highly effective method of birth control&#xD;
&#xD;
          -  Willing and able to give informed consent&#xD;
&#xD;
          -  Additional inclusion criteria apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has fulminant colitis, toxic megacolon, primary sclerosing cholangitis, Crohn's&#xD;
             disease, history of colitis-associated colonic dysplasia, active peptic ulcer disease&#xD;
&#xD;
          -  Medications of exclusion: a) azathioprine, 6-mercaptopurine, or methotrexate within&#xD;
             the 28 days prior to Day 1, b) adalimumab, infliximab, golimumab, etanercept, or&#xD;
             certolizumab within the 60 days prior to Day 1, c) intravenous corticosteroids within&#xD;
             the 14 days prior to Day 1, d) topical mesalamine or steroid (i.e., enemas or&#xD;
             suppositories) within the 14 days prior to Day 1, e) any prior exposure to&#xD;
             mycophenolic acid, tacrolimus, sirolimus, cyclosporine, natalizumab, rituximab,&#xD;
             efalizumab, ustekinumab, fingolimod, or thalidomide, f) NSAIDs on a daily basis, g)&#xD;
             tofacitinib within the 60 days prior to Day 1; h) vedolizumab within 120 days prior to&#xD;
             Day 1&#xD;
&#xD;
          -  Has a current bacterial, parasitic, fungal, or viral infection&#xD;
&#xD;
          -  Is positive for hepatitis A, B or C, HIV or tuberculosis&#xD;
&#xD;
          -  Has clinically significant abnormalities in laboratory evaluations&#xD;
&#xD;
          -  Participated in another clinical trial of an investigational drug (or medical device)&#xD;
             within 30 days prior to screening (or within 60 days prior to screening if&#xD;
             investigational drug was a biologic or another Janus kinase (JAK) inhibitor, or is&#xD;
             currently participating in another trial of an investigational drug (or medical&#xD;
             device)&#xD;
&#xD;
          -  Use of prescription medications started or with a dose adjustment within 4 weeks prior&#xD;
             to study enrollment, or over-the-counter medications or supplements started or with a&#xD;
             dose adjustment within 2 weeks prior study enrollment. Anti-diarrheal medications are&#xD;
             allowed only if dose has been stable at least 2 weeks prior to study enrollment&#xD;
&#xD;
          -  Additional exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0141</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Chisinau</city>
        <zip>MD-2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>50152</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://academic.oup.com/ecco-jcc/advance-article/doi/10.1093/ecco-jcc/jjaa049/5803305</url>
    <description>&quot;Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme&quot; in the Journal of Crohn's and Colitis</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative Colitis, Active Moderate and Severe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

